Role of vindesine as neoadjuvant chemotherapy for non-small cell lung and head and neck cancers

Anti-Cancer Drugs

Volumn 8, Issue 8, 1997, Pages 734-745

  Cvitkovic, Esteban ^a   Wasserman, Ernesto ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Head and neck cancer; Lung cancer; Neoadjuvant chemotherapy; Vindesine

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NAVELBINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; VINDESINE;

EID: 0030882438     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199709000-00002     Document Type: Review

References (76)

1. Williams DE, Pairolero PC, Davis CS, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82: 70-6.
2. Naruke T. Bronchoplastic and bronchovascular procedures of the tracheobronchial tree in the management of primary lung cancer. Chest 1989; 96: 53S-63S.
3. Ginsberg RJ. Limited resection in the treatment of stage I non-small cell lung cancer: an overview. Chest 1989; 96: 50S-1S.
4. Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989; 139: 902-10.
5. Salvatierra A, Baamonde C, Llama JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97: 1052-8.
6. Rosell R, Font A, Pifarré A, et al. The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996; 109: 102S-6S.
7. Browman GP. Evidence-based recommendations against neoadjuvant chemotherapy for routine management of patients with squamous cell head and neck cancer. Cancer Invest 1994; 12: 662-71.
8. Pujol JL, Le Chevalier T, Ray P, et al. Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer. Lung Cancer 1995; 12: S107-18.
9. Bunn PA. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol 1994; 21: 49-59.
10. American Joint Committee on Cancer. In: Manual for staging of cancer, 4th edn. Philadelphia: Lippincott 1992: 115-22.
11. Pisters K, Kris M, Gralla R, et al. Preoperative chemotherapy in stage IIIA non-small cell lung cancer: an analysis of a trial in patients with clinical apparent mediastinal node involvement. In: Salmon S, eds. Adjuvant therapy of cancer VI. Philadelphia: Saunders 1990: 133-7.
12. Martini N, Flehinger B, Zaman M, et al. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198: 386-97.
13. Roth JA, Fosella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80.
14. Rosell R, Goméz-Codina J, Camps C, et al. A randomized trial comparing pre-operative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153-8.
15. Depierre A, Milleron B, Lebeau B, et al. An ongoing randomized study of neoadjuvant chemotherapy in resectable nun-small cell lung cancer. Semin Oncol 1994; 21: 16-9.
16. Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trail of neoadjuvant therapy for lung cancer: an interim analysis. Ann Thorac Surg 1992; 53: 992-8.
17. Dautzenherg B, Benichou J, Allard P, et al. Failure of the perioperative PCV neoadjuvant poly-chemotherapy in resectable hronchiogenic non-small cell carcinoma. Results from a randomized phase II trial. Cancer 1990; 65: 2435-41.
18. Fischer JR, Manegold C, Bulzebruck H, Vogt-Moykopf I, Drings P. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-ssmall cell lung cancer. Semin Oncol 1994; 21: 20-7.
19. Macchiarini P, Calipelier AR, Monnet I, et al. Extended operations after induction therapy for stage IIIb non-small cell lung cancer. Ann Thorac Surg 1994; 57: 966-73.
20. Sorensen JB, Hansen HH. Is there a role for vindesine in the treatment of non-small cell lung cancer. Invest New Drugs 1993; 11: 103-33.
21. Dancey J, Steward WP. The role of vindesine in oncology - recommendations after 10 years' experience. Anti-Cancer Drugs 1995; 6: 625-36.
22. Fukuoka M, Masuda N, Furuse K, et al. A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 1991; 9: 606-13.
23. Kris MG, Gralla RJ, Kalman RA, et al. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985; 69: 387-95(a).
24. Elliott JA, Ahmedzai S, Hole D, et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 1984; 20: 1025-32.
25. Gralla RJ, Raphael BG, Colby RB, Young CW. Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treat Rep 1979; 63: 1343-6.
26. Miller TP, Vance RB, Ahmann FR, Rodney SR. Extensive non-small cell lung cancer treated with mitomycin, cisplatin and vindesine (MiPE): a Southwest Oncology Group study. Cancer Treat Rep 1986; 70: 1101-5.
27. Kris G, Gralla RJ, Wartheim MS, et al. Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 1986; 70: 1096-7.
28. Gralla RJ, Kris MG, Burke DP, Kelsen DP, Heelan R. The influence of the addition of mitomycin to vindesine plus cisplatin in a random assignment trial in 120 patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1986; 5: (abstr 714).
29. Kris MG, Gralla RJ, Kelsen DP, et al. Trial of vindesine plus mitomycin in Stage III non-small cell lung cancer: an active regimen for outpatient treatment. Chest 1985; 87: 368-73(b).
30. Luedke D, Leudke S, Martello O, et al. Response of non-small cell lung cancer (NSCLC) to vindesine (VDS) and mitomycin-c (MITO): a Southeastern Cancer Study Group pilot study. Proc Am Soc Clin Oticol 1983; 2: (abstr 190).
31. Weick JK, Purvis JD, Livingston RB. Divided dose vinblastine and mitomycin-C (VEMI) in extensive non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 1981; 1: 151.
32. Miller TP, McMahon LJ, Livingstone RB. Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine and mitomycin-C (FOMi). Cancer Treat Rep 1980; 64: 1241-5.
33. Miller TP, Chen TT. Alternating combination chemotherapy prolongs survival for metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1983; 2: 188 (abstr).
34. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-74.
35. Rosell R, Abad-Esteve A, Morend I, et al. A randomized study of two vindesine plus cisplatin containing regimens with the addition of ifosfamide in patients with advanced non-small cell lung cancer. Cancer 1990; 8: 1692-9.
36. Spain RC. The case of mitomycin in non-small cell lung cancer. Oncology 1993; 50: 35-52.
37. Setoguchi J, Sawada M, Onodara H, et al. Clinical study of combination hemotherapy with mitomycin C, vindesine and cisplatin in advanced non-small cell lung cancer. Gan To Kagaku Ryoho 1989; 16: 2399-403.
38. Elias AD, Skarin AT, Gonin R, et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994; 17: 26-36.
39. Spain RC. Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: problems and progress from the perspective of long-term follow up. Semin Oncol 1988; 15: 6-15.
40. Strauss CM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: report of a cancer and leukemia group B phase II study. J Clin Oncol 1992; 10: 1237-44.
41. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10: 580-6.
42. Sridhar KS, Thurer R, Markoe AM, et al. Multidisciplinary approach to the treatment of locally and regionally advanced non-small cell lung cancer. Semin Surg Oncol 1993; 9: 114-9.
43. Pujol JL, Hayot M, Rouanet P, et al. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. Chest 1994; 106: 1451-55.
44. Weiden P, Piantadosi S. Preoperative chemoradiotherapy (cisplatin and fluorouracil) and radiation therapy in stage in non-small cell lung cancer: a phase II study of the LCSG. Chest 1994; 106: 344S-7S.
45. Merlano M, Benasso M, Cavallari M, et al. Chemotherapy in head and neck cancer. Oral Oncol, Eur J Cancer 1994; 30B: 283-9.
46. Pacagnella A, Orlando A, Machiori C, et al. Phase II trial of initail chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-72.
47. Leyvraz S, Barrelet L, Savary M, Bernasconi S. Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma. Cancer Treat Rep 1987; 71: 81-2.
48. Tellez-Bernal E, Recondo JG, Guillot T, et al. A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer. Cancer 1990; 66: 640-4.
49. Jaulerry C, Rodriguez J, Brunin F, et al. Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. Int J Radiat Oncol Biol Phys 1992; 23: 483-9.
50. Merlano M, Corvo R, Margarino G, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. Cancer 1991; 67: 915-21.
51. Pfister DG, Strong E, Harrison L, et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J Clin Oncol 1991; 9: 850-9.
52. Pfister DG, Harrison LB, Strong EW, et al. Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiation. J Clin Oncol 1995; 13: 671-80.
53. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90.
54. Lefebvre J-L, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-9.
55. Mehta M, Larson MM, Pharo L, et al. Phase II clinical trial of amifostine, cisplatin, vinblastine and radiation therapy for unresectable stage III non small cell lung cancer. Proc Am Soc Clin Oncol 1995; 373: (abstr 1152).
56. International Nasopharynx Cancer Study Group. Prelminary results of a randomised trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy versus radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effects on progression-free survival. Int J Radiat Oncol Biol Phys 1996; 35: 463-1.
57. Vokes EE, Bitran JD, Hoffman PC, et al. Neoadjuvant vindesine, etoposide and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase II study. Chest 1989; 96: 110-3.
58. Gridelli C, Lacobelli S, Martino T, et al. Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIa-IIIB non-small cell lung cancer: a pilot study. Tumori 1992; 78: 377-9.
59. Darwish S, Minotti V, Crino L, et al. Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer. Am J Clin Oncol 1994; 17: 64-7.
60. Sugarbaker DJ, Herndon J, Kohman J, et al. Results of Cancer and Leukemia Group B protocol 8935. A multiinstitutional phase II trimodality trail for stage IIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 473-85.
61. Bonomi P, Rowland K, Taylor SG. Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil and simultaneous split course radiation therapy in stage III non-small cell bronchiogenic carcinoma. Semin Oncol 1986; 13: 115-20.
62. Eagan R, Ruud C, Lee R, et al. Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cis-platin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 1987; 1: 895-900.
63. Taylor SG, Trybula M, Bonomi PD, et al. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III non-small cell lung cancer. Ann Thorac Surg 1987; 43: 87-91.
64. Pincus M, Reddy S, Lee MS. Preoperative combined modality therapy for stage III M0 non-small cell lung cancer, Int J Radiother Oncol Biol Phys 1988; 15: 189-95.
65. Deutsch MA, Leopold KA, Crawford J, et al. Garboplatin, etoposide and radiotherapy followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. Cancer Treat Rev 1993; 19: 53-62.
66. Knowlton AH, Percarpio B, Bobrow S, Fischer JJ. Methotrexate and radiation therapy in the treatment of advanced head and neck tumors. Radiology 1975; 116: 709-12.
67. Fazekas JT, Sommer C, Kramer S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. Int J Radiat Oncol Biol Phys 1980; 6: 533-41.
68. Petrovich Z, Block J, Kuisk H, et al. A randomized comparison of radiotherapy with a radiotherapy-chemotherapy combination in stage IV carcinoma of the head and neck. Cancer 1981; 47: 2259-64.
69. Stell PM, Dalby JE, Strickland P, et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 1986; 12: 173-8.
70. Kun KE, Toohill RJ, Holoye PY, et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 1986; 12: 173-8.
71. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Cancer 1987; 60: 301-11.
72. Toohill RJ, Anderson T, Byhardt RW, et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. Arch Otlaryngol Head Neck Surg 1987; 113: 758-61.
73. Schuller DE, Metch B, Mattox D, Stein DW, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the South-west Oncology Group. Laryngoscope 1988; 98: 1205-11.
74. Martin M, Hazan A, Vergnes L, et al. Randomized study of 5 fluorouracil and cisplatin as neoadjuvant therapy in head and neck cancer: a preliminary report. Int J Radiat Oncol Biol Phys 1990; 19: 973-5.
75. Mazeron JJ, Martin M, Brun B, et al. Induction chemotherapy in head and neck cancer: results of a phase III trial. Head & Neck 1992; 14: 85-91.
76. Salvajoli JV, Morioka H, Trippe N, Kowalski LP. A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 1992; 249: 211-5.